SCHEMBL29360772

SCHEMBL29360772

c1ccc(-c2c[nH]nc2Oc2cc[nH]n2)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.38
▸ NPC1 O15118 5/20 0.38
▸ RAB9A P51151 5/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ CCR1 P32246 2/20 0.37
▸ CCR5 P51681 2/20 0.37
▸ CCR8 P51685 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ METAP1 P53582 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ DOHH Q9BU89 1/20 0.37
▸ P4HTM Q9NXG6 1/20 0.37
▸ PRKCI P41743 1/20 0.37
▸ METAP2 P50579 1/20 0.35
▸ TDP1 Q9NUW8 3/20 0.33
▸ TP53 P04637 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29882339 0.78 SQOR (0.32) ALOX15MAPK1ALDH1A1
SCHEMBL25276134 0.76 KDM4E (0.44) KDM4ENPC1RAB9AMAPTATM
SCHEMBL1817017 0.72 KDM4E (0.43) KDM4ENPC1RAB9ALMNACCR1
SCHEMBL10884670 0.71 PRKCI (0.35) KDM4ENPC1RAB9AMAPTLMNA
SCHEMBL1924499 0.71 KDM4E (0.48) KDM4ENPC1RAB9AMAPTLMNA
SCHEMBL3463943 0.71 KDM4E (0.48) KDM4ENPC1RAB9AMAPTLMNA
SCHEMBL31374417 0.71 KDM4E (0.42) KDM4ENPC1RAB9ALMNACCR1
SCHEMBL10921322 0.69 KDM4E (0.46) KDM4ENPC1RAB9AMAPTLMNA
SCHEMBL1384700 0.69 KDM4E (0.46) KDM4ENPC1RAB9AMAPTLMNA
SCHEMBL31339152 0.69 KDM4E (0.46) KDM4ENPC1RAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022017208-A1 SALT FORM AND CRYSTAL FORM OF PYRIDYLOXY PYRAZOLE COMPOUND AS TGF-βR1 INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF 江苏奥赛康药业有限公司 2022-01-27 — — WO disclosed
Send feedback